Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
Stanley Cohan1,2,3 1Providence Multiple Sclerosis Center, 2Providence Brain and Spine Institute, 3Providence Health & Services, Portland, OR, USA Abstract: Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly...
Saved in:
Main Author: | Cohan S |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/a2a044b93820402db845b0bff30c7a2d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
by: Tran JQ, et al.
Published: (2016) -
Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
by: Elsbernd PM, et al.
Published: (2021) -
Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
by: Konrad Rejdak, et al.
Published: (2021) -
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
by: Sylwia Pietrasik, et al.
Published: (2021) -
Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
by: Ratthaporn Boonsuth, et al.
Published: (2021)